P3 Health Partners Inc. (PIIIW)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -76.02 Million | -126.01 Thousand | -66.47 Million | -24.59 Million | -28.28 Million | -29.23 Million |
| Net Income | -57.77 Million | -1.56 Million | -156.48 Million | -45.38 Million | -41.97 Million | -49.77 Million |
| Depreciation & Amortization | 86.67 Million | 87.28 Thousand | 8.72 Million | 795.17 Thousand | 399.17 Thousand | 342.19 Thousand |
| Deferred income taxes | -157.15 Million | - | -8.24 Billion | -20.53 Million | 6.36 Million | - |
| Stock-based compensation | 5.97 Million | 19.4 Million | 8.33 Million | 447.47 Thousand | 474.04 Thousand | 447.05 Thousand |
| Change in working capital | 30.29 Million | 34.81 Thousand | 75.77 Million | 33.12 Million | 8.06 Million | 4.34 Million |
| Other non-cash items | 15.94 Million | 1.29 Million | -46.24 Million | 6.95 Million | -1.62 Million | 15.4 Million |
| Investing Cash Flow | -1.82 Million | -7733.00 | -56.06 Million | -3.16 Million | -3.85 Million | -4.59 Million |
| Investments in PPE | -1.82 Million | -2233.00 | -3.41 Million | -2.92 Million | -1.45 Million | -3.3 Million |
| Acquisitions | - | -5500.00 | -52.86 Million | -130 Thousand | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | 213.94 Thousand | -109.52 Thousand | -2.4 Million | -1.29 Million |
| Financing Cash Flow | 100.33 Million | 11.37 Thousand | 223.46 Million | 34.76 Million | 63.61 Million | 33.25 Million |
| Debt repayment | -13.75 Million | -3625.00 | -28.15 Million | -1.49 Million | -14.58 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -16 Thousand | - | - | -180 Thousand | - | - |
| Common Stock Issuance | 86.59 Million | - | 195.3 Million | -180 Thousand | 62.04 Million | - |
| Other Financing Activities | -16 Thousand | 15 Thousand | 198.66 Million | 36.79 Million | 16.16 Million | - |
| Accounts receivables | -41.99 Million | -5.33 Million | 448.14 Thousand | 139.21 Thousand | 424.13 Thousand | -1.38 Million |
| Accounts payables | 64.17 Million | 6082.00 | 68.75 Million | 8.1 Million | 803.5 Thousand | 2.11 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 8.11 Million | 5.36 Million | 6.57 Million | 24.88 Million | 6.84 Million | 3.61 Million |
| Cash at beginning of period | 18.45 Million | 140.83 Thousand | 39.9 Million | 32.9 Million | 1.42 Million | 2.01 Million |
| Cash at end of period | 40.93 Million | 18.45 Thousand | 140.83 Million | 39.9 Million | 32.9 Million | 1.42 Million |
| Capital Expenditure | -1.82 Million | -2233.00 | -3.41 Million | -2.92 Million | -1.45 Million | -3.3 Million |
| Effect of forex changes on cash | - | - | 5.35 Million | - | - | - |
| Net cash flow / Change in cash | 22.47 Million | -122.37 Thousand | 100.93 Million | 6.99 Million | 31.47 Million | -585.07 Thousand |
| Free Cash Flow | -77.85 Million | -128.25 Thousand | -69.88 Million | -27.52 Million | -29.73 Million | -32.54 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -12.02 Million | -18.7 Million | -25.46 Million | -57.77 Million | -37.28 Million | -27.58 Million |
| Depreciation & Amortization | 21.69 Million | 21.53 Million | 21.63 Million | 86.67 Million | 21.72 Million | 21.78 Million |
| Deferred income taxes | - | - | -11.68 Million | -157.15 Million | -13.24 Million | -281 Thousand |
| Stock-based compensation | 1.62 Million | 1.44 Million | 1.72 Million | 5.97 Million | 2.25 Million | 1.03 Million |
| Change in working capital | 7.23 Million | 5.94 Million | 33.91 Million | 30.29 Million | 18.91 Million | -23.85 Million |
| Other non-cash items | 9.94 Million | 10.9 Million | -35.99 Million | 15.94 Million | 65 Thousand | 61 Thousand |
| Investing Cash Flow | - | - | 212 Thousand | -1.82 Million | -387 Thousand | -1.18 Million |
| Investments in PPE | - | - | 212 Thousand | -1.82 Million | -387 Thousand | -1.18 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 56.13 Million | 11.4 Million | -840 Thousand | 100.33 Million | -86 Thousand | 87.15 Million |
| Debt repayment | -13.93 Million | -11.44 Million | -175 Thousand | -13.75 Million | -1000.00 | -173 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -30 Thousand | -73 Thousand | -649 Thousand | -16 Thousand | -85 Thousand | - |
| Common Stock Issuance | 42.23 Million | 33 Thousand | -649 Thousand | 86.59 Million | -85 Thousand | 87.32 Million |
| Other Financing Activities | -30 Thousand | -73 Thousand | -16 Thousand | -16 Thousand | 171 Thousand | 87.15 Million |
| Accounts receivables | -11.68 Million | -22.3 Million | -2.01 Million | -41.99 Million | -15 Million | -6.24 Million |
| Accounts payables | 17.97 Million | 25.67 Million | 35.31 Million | 64.17 Million | 834 Thousand | -6.39 Million |
| Inventory | - | - | - | - | 15 Million | 6.24 Million |
| Other working capital | 947 Thousand | 2.57 Million | 612 Thousand | 8.11 Million | 18.07 Million | -17.45 Million |
| Cash at beginning of period | 32.3 Million | 40.93 Million | 57.44 Million | 18.45 Million | 65.49 Million | 8.37 Million |
| Cash at end of period | 78.2 Million | 32.3 Million | 40.93 Million | 40.93 Million | 57.44 Million | 65.49 Million |
| Capital Expenditure | - | - | 212 Thousand | -1.82 Million | -387 Thousand | -1.18 Million |
| Effect of forex changes on cash | - | - | - | - | -5.25 Million | -111.72 Million |
| Net cash flow / Change in cash | 45.89 Million | -8.62 Million | -16.5 Million | 22.47 Million | -8.05 Million | 57.12 Million |
| Free Cash Flow | -10.24 Million | -20.03 Million | -15.66 Million | -77.85 Million | -7.97 Million | -30.03 Million |
ML
SPFX
CONFRZ
002200
LBE
AOVTF